Patricia M. Dowling

Associations Between Feed and Water Antimicrobial Use in Farrow-to-Finish Swine Herds and Antimicrobial Resistance of Fecal Escherichia coli from Grow-Finish Pigs

Escherichia coli (n = 1439), isolated from the feces of apparently healthy grow-finish pigs in 20 herds, were tested for susceptibility to 16 antimicrobials. Logistic regression models were developed for each resistance that was observed in more than 5% of the isolates. Each production phases (suckling, nursery, grow-finish pigs or sows) antimicrobial exposure rate, through feed or water, was considered as a risk factor. Management variables were evaluated as potential confounders. Six resistance outcomes were associated with an antimicrobial use risk factor and four included exposures of pigs outside the grow-finish phase. In the case of sulfamethoxazole, the odds of resistance increased 2.3 times for every 100,000 pig-days of nursery pig exposure to sulfonamides. Thus, swine producers and veterinarians must be aware that antimicrobial use in pigs distant from market could have food safety repercussions. Five resistance outcomes were associated with exposure to an unrelated antimicrobial class. Most notably, the odds of sulfamethoxazole and chloramphenicol resistance were each six times higher in herds reporting high (more than 500/1,000 pig-days) grow-finish pig, macrolide exposure compared to herds with no macrolide use in grow-finish pigs. Therefore, the potential for co-selection should be considered in antimicrobial use decisions. This study emphasizes the importance of judicious antimicrobial use in pork production.

The Analysis of Phenylbutazone and Its Active Metabolite, Oxyphenbutazone, in Equine Tissues (Muscle, Kidney, and Liver), Urine, and Serum by LC-MS/MS

This study reports the use of two validated LC with tandem MS (MS/MS) methods to study the residue depletion profile of phenylbutazone (PBZ) and its metabolite oxyphenbutazone (OXPBZ) from equine serum, urine, and muscle, kidney, and liver tissues. One LC-MS/MS method, with an LOQ of 1.0 ng/mL for PBZ and 2.0 ng/mL for OXPBZ, was used for the analysis of the two drugs in the biological fluids (equine urine and serum); the other LC-MS/MS method, with an LOQ of 0.5 ng/g for PBZ and OXPBZ, was used for the analysis of the drugs in the equine tissue samples. PBZ was administered intravenously to two horses dosed with 8.8 mg/kg PBZ once daily for 4 days and sacrificed humanely at a slaughter plant 7 days after the last drug administration. Urine, serum, and kidney, liver, and muscle tissues were collected from the two horses and shipped on ice to the laboratory and stored at -20°C until analysis. The concentrations of PBZ and OXPBZ residues in the biological fluid and tissue samples collected at slaughter were measured with the two validated LC-MS/MS methods using deuterated internal standards. The results demonstrate that the validated methods are fit for studying the depletion kinetics of PBZ residues in equine tissues and biological fluids.